SPARC0921
Phase 3Small molecule
Sun Pharma Advanced Research Company LimitedSPARC0921 is one of 32 small molecule programs targeting Spasticity. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
57 competitors in Spasticity
#DrugCompanyPhaseTrials
1Lioresal
NovartisApproved
Namenda
AbbVieApproved
Zanaflex
LLegacy Health System
Approved
Cesamet
BBausch Health Americas, Inc.
Approved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Meditoxin
MMedy-Tox
Approved
Botox
AbbViePhase 3
Onabont-a
IpsenApproved
GSK1358820
GSKPhase 3
Sativex
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SPARC0921. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details